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1 
Highlights 
 
 The present paper aimed at collecting recommendations on non-pharmacological treatment 
(NPT) for apathy and on the role of new Information and Communication Technologies 
(ICT) in this domain.  
 Based on the experts’ opinion, NPT should be tailored to deficits, clinical objectives, and 
preferences of each patient. ICT may help to improve treatment personalization, increase 
motivation, and aid remote treatment delivery.  
 Further structured research is needed to determine NTP efficacy. 
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Abstract 
 
Apathy is a common neuropsychiatric syndrome observed across many neurocognitive and 
psychiatric disorders. Although there are currently no definitive standard therapies for the treatment 
of apathy, non-pharmacological treatment (NPT) is often considered to be at the forefront of clinical 
management. However, guidelines on how to select, prescribe and administer NPT in clinical 
practice are lacking. Furthermore, although new Information and Communication Technologies 
(ICT) are beginning to be employed in NPT, their role is still unclear. The objective of the present 
work is to provide recommendations for the use of NPT for apathy, and to discuss the role of ICT in 
this domain, based on opinions gathered from experts in the field. The expert panel included 20 
researchers and healthcare professionals working on brain disorders and apathy. Following a 
standard Delphi methodology, experts answered questions via several rounds of web-surveys, and 
then discussed the results in a plenary meeting. The experts suggested that NPT are useful to 
consider as therapy for people presenting with different neurocognitive and psychiatric diseases at 
all stages, with evidence of apathy across domains. The presence of a therapist and/or a caregiver is 
important in delivering NPT effectively, but parts of the treatment may be performed by the patient 
alone. NPT can be delivered both in clinical settings and at home. However, while remote treatment 
4 
delivery may be cost and time-effective, it should be considered with caution, and tailored based on 
the patient’s cognitive and physical profile and living conditions.  
Implications for Practice and Research. NPT should be tailored to deficits (e.g., cognitive, 
physical), clinical objectives (e.g. prevention, intervention) and preferences (e.g. personal, sensory) 
of each patient. ICT may help to improve treatment personalization, increase motivation, and aid 
remote treatment delivery. Further structured research (e.g., RCT) is needed to determine NPT 
efficacy. 
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Introduction 
In various brain disorders, apathy is consistently defined as a multidimensional syndrome 
characterized by a significant reduction in goal-directed activity1-5. Different apathy dimensions or 
subtypes include symptoms in relation to behavior (reduced level of activity, initiative), cognition 
(reduced interests, motivation for planning), emotions (emotional blunting, indifference, affective 
flattening) and social interaction (reduced social activities and engagement)3-5. Apathy is prevalent across 
many neurocognitive disorders (NCD, DSM-56) and psychiatric disorders (PSY). It represents the most 
common behavioural and psychological symptom in people with Alzheimer’s Disease (AD), and is often 
observed in Parkinson’s disease (PD), vascular dementia, stroke, traumatic brain injury, amyotrophic 
lateral sclerosis/motor neurone disease (ALS/MND), frontotemporal dementia, progressive supranuclear 
palsy (PSP), small vessel disease, major depression and schizophrenia7. 
Pharmacological therapies have demonstrated limited efficacy in the management of apathy 
associated with NCD and neuropsychiatric conditions. Methylphenidate has been observed as 
potentially beneficial in reducing levels of apathy in people with AD, and rivastigmine may be beneficial 
for people with PD, but these findings are associated with weak evidence8-9. Non-pharmacological 
treatment (NPT) - or ecopsychosocial interventions10 - are often considered to be at the forefront of 
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apathy management11. NPTs aim to address the cognitive, psychological, social, personal and relational 
functioning of the person. Usually these interventions use a “person-centered” rather than a “symptom-
centered” approach, since they address not only the primary symptoms of a condition, but also the 
secondary experiences that arise as a consequence of the condition12.  NPTs include a wide range of 
methods, such as group activities, therapeutic dialogs, meditation, and sensory, physical and 
physiological stimulation (Table 1). The scope of NPTs is broad and covers different dimensions such as 
cognition, motor skills, functional abilities, psycho-behavioral symptoms, social life and self-esteem. The 
general goals of these types of interventions are to strengthen cognitive, psycho-affective and social 
skills to reduce psycho-behavioral symptoms, to preserve the patient's social activity, to restore 
confidence and self-esteem and to promote autonomy as well as quality of life13.  
A variety of NPTs (symptom specific and symptom non-specific) have proven useful for the 
treatment of apathy. In people with Mild and Major NCD, for example, NPTs have been shown to be 
effective in improving apathy administered alone11 or combined with drug therapy14,15. A summary of 
the NPTs employed to reduce apathy (as a direct or indirect target), and the clinical populations on 
which they have been employed is presented in Table 1 (see11,14,16 for more exhaustive reviews).   
 
[Table 1] 
 
Information and Communication Technologies (ICT) have also started to be employed in 
NPTs to train cognitive and physical functions, promote communication, reduce loneliness and 
improve the emotional state in apathetic and non-apathetic patients. These include, Virtual 
Reality
32
, Serious Games (i.e., video-games designed to train cognitive and/or physical 
functions
18,36
), and social robots
11. Remote NPT delivery through telemedicine interfaces is also 
starting to be explored for elderly people with cognitive impairment
37
. 
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 Although most studies of NPTs have demonstrated promising results, the improvements in 
apathy do not seem long-lasting (from one week to several months, depending on the study)
38
, and 
results have been difficult to reproduce due to variability in the treatment delivery and conditions
11
. 
In most of the existing Randomized Controlled Trials (RCT), apathy was not the primary 
intervention target and the main endpoint. Similarly, apathy was rarely measured using multi-
dimensional scales.
 
The wide variability in sample size, diagnosis, apathy assessment, follow-up 
duration, and intervention conditions make it hard to provide strong conclusions on NPT efficacy in 
apathy management
7
. The field would benefit from more well-designed clinical studies (RCT) 
employing apathy as the main endpoint. These studies could focus on understanding which 
treatments are most effective for different pathologies, and in which conditions, as well as where, 
when, and how often they should be implemented. The objective of the present work was to gather 
recommendations from experts in the field concerning the use of NPTs for apathy, and the role of 
ICT in delivering NPTs. 
Methods 
The task force included 20 experts (researchers and healthcare professionals) in the domain 
of apathy in NCD and PSY. The experts were from 8 different countries (France, United Kingdom, 
USA, Italy, Brazil, Spain, Chile, the Netherlands). The experts’ main professional backgrounds 
were Psychiatry (N=8), Psychology (N=8), Neurology (N=2), Speech Therapy (N=1) and ICT 
(N=1). All of them had more than five years of experience in the domain of apathy (9 participants 
with 5 to 10 years of experience, 5 participants with 10 to 20 years of experience, and 6 participants 
with more than 20 years of experience).  Following a standard Delphi methodology
39
 the 
recommendations were developed in a two-step process: web-surveys followed by a consensus 
meeting. 
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Web-surveys 
The experts were asked to answer questions via a web-survey in three rounds (between 
November 2018 and March 2019) using Microsoft Forms. After each round, a facilitator (PR) 
provided a summary of the experts’ responses, and encouraged the experts to analyze, comment and 
(eventually) revise their earlier responses considering the commentaries of other members of the 
panel. Questions in the three rounds included 13 rating questions (Supplementary Table 1): 9 
(questions 1 to 9) focused on classical NPTs, 4 (questions 10 to 13) on the use of new ICT in NPT. 
For each question, participants rated their degree of agreement by employing a 5-point Likert scale 
(1=Not important/pertinent at all; 2=Not very important/pertinent; 3=Important/Pertinent; 4=Very 
important/pertinent; 5=Extremely important/pertinent). After each rating question, participants 
could provide comments. Round 1 also included the following open question: “Please report the 3 
most important limitations and benefits of using ICT in NPT for apathy”. The list of reported 
benefits and limitations was employed as a starting point to perform a SWOT analysis (Strengths, 
Weaknesses, Opportunities, and Threats) of the use of ICT for NPTs. Several open questions were 
asked in rounds 2 and 3 to comment on the responses provided in rounds 1 and 2. After round 2, a 
first draft of the recommendations was circulated among the experts.  
Final consensus meeting 
The three web-surveys’ results and the open discussion points were revised by the task force 
during a plenary meeting held on March 8, 2019 in Nice (France).  
 
Results  
The results of the rating questions (median and interquartile range, IQR) are reported in 
Supplementary Table 1. The number of responses obtained for each question ranged from 14 to 16.  
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General questions  
NPT for whom (Q1). The experts reported that NPTs for apathy are ‘extremely important’ 
for patients with Major NCD (defined in the DSM-5 as a significant cognitive decline interfering in 
the independence of the individual with relation to everyday activities due to pathologies including 
AD, PD and other neurodegenerative disorders), and ‘very important’ for people with schizophrenia 
/ psychotic disorders, depressive disorders, and Mild NCD (defined in the DSM-5 as a noticeable 
decrement in cognitive functioning that goes beyond normal changes seen in aging, with 
independence and autonomy is activities of daily living preserved thanks to compensatory 
strategies). Apathy NPTs were rated as ‘important’ for people with Post-Traumatic Stress 
Disorders, and subjective cognitive decline (SCD, characterized by cognitive complaints associated 
to unimpaired performance on cognitive tests). The difference in level of importance was reported 
mainly because apathy shows a higher prevalence in patients with severe impairments
40,41
. The 
experts also considered NPTs to be important for targeting apathy in the context of limbic and 
paralimbic tumors, personality disorders, Traumatic Brain Injury, stroke, small vessel disease, and 
ASL/MND. 
NPT for what (Q2). Participants considered apathy NPTs to be ‘extremely important’ or 
‘important’ for patients presenting symptoms in the different dimensions listed in the 2018 
Diagnostic Criteria for Apathy, namely behavior/cognition, emotion and social interaction
3
. Apathy 
is consistently described as a multidimensional construct, and it is recognized that different apathy 
dimensions may be differently impaired in different pathologies
5,41
 and have different neural 
substrates
42
. Different NPTs may be suitable to help those with impairments in different apathy 
dimensions. However, there is not enough evidence suggesting differential efficacy of NPTs for 
specific apathy dimensions, as studies typically employ global apathy measures only
11
. In addition, 
there is still no final consensus on the number and type of apathy dimensions, meaning that 
different apathy scales capture different apathy dimensions
43-45
. The experts acknowledged the need 
9 
and importance for further research in order to converge in the understanding of the construct of 
apathy. Additionally, experts acknowledged the need to determine whether NPT treatments 
targeting specific apathy dimensions may also be useful to target conditions showing a partial 
overlap with apathy, such as anhedonia, depression and chronic fatigue
7
. 
NPT based on what. When asked what factors are the most important for selecting the best 
NPT (Q3), the level of severity of the disease (cognitive and functional impairment) was rated as 
‘extremely important’, while the age of the patient and the environment and lifestyle were rated as 
‘very important’. Participants acknowledged that it is ‘extremely important’ to choose NPT based 
on the personal interests and sensory preferences (e.g., favorite colors, music, odors; Q4). This is in 
line with previous research suggesting that personalized interventions are a key aspect to improve or 
maintain treatment adherence and efficacy
11
. The most appropriate methods to collect patient’s 
needs and interests (Q5) were structured and semi-structured interviews, ICT and Serious Games 
(‘very appropriate’), while open questions were rated as between ‘appropriate’ and ‘very 
appropriate’. The most appropriate methods to collect patients’ sensory preferences (Q6) were 
observation by exposure, semi-structured interviews, and ICT/serious games (‘very appropriate’), 
while assessment performed by others (clinicians or caregivers) was rated between ‘appropriate’ 
and ‘very appropriate’, and self-evaluation as ‘appropriate’. The experts highlighted the importance 
of developing standardized tests to collect patients’ sensory preferences, which should be validated 
and compared to what is obtained in observation by exposure or observed in routine care.  
Multisensory interventions, in which several senses are stimulated simultaneously, have 
showed promising results in reducing apathy
11
, however, which (and how many) senses should be 
stimulated is still debated
46
. Participants reported that in multi-sensory interventions it is ‘very 
appropriate’ to stimulate sight, hearing, smell and touch, and that stimulating taste is rated as 
between ‘appropriate’ and ‘very appropriate’ (Q7), mainly due to difficulties in materials available 
(e.g., the use of foods and drinks in a therapeutic setting).  
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NPT with whom. In Q8 participants reported that it is ‘very pertinent’ to administer NPT in 
individual sessions, while it is ‘pertinent’ to administer them in group sessions. The preference for 
individual sessions was mainly explained by the need for achieving personalized objectives. 
Patients with different types and degrees of impairment, different deficits and different personal 
preferences should be stimulated in different ways. However, group sessions might be relevant to 
stimulate social interactions. The presence of a therapist (physical or virtual) was reported as a key 
element in designing NPT. Indeed, the interaction with the therapist can promote positive emotions 
and affect, which can be useful in facilitating patients’ motivation and maintain engagement in the 
treatment. But it was acknowledged that the therapist would not necessarily have to be present 
continuously. For instance, through ICT, patients may also continue treatment sessions alone
18
.  
When. To decide if and when to prescribe or administer NPT for apathy (Q9), participants 
reported that it is ‘extremely important’ that the patient and/or caregivers consider apathy as a 
problem. The availability of NPT adapted to the patient’s needs, the patient’s willingness to adhere 
to the NPT and the stage of the disease were rated as ‘very important’. It was acknowledged that the 
decision of whether to propose NPT for apathy should be taken by clinicians in collaboration with 
patients and caregivers. Therefore, it is important to examine the mechanisms that lead to apathy, 
and not see apathy as a symptom that always requires treatment. For instance, apathy in people at 
the end of life may not be appropriate to target for therapeutic intervention. 
 
Questions focused on ICT 
ICT for NPT. Participants reported that ICT is ‘very appropriate’ for apathy NPT (Q10). All 
participants (N=15) agreed that there is a good benefit/risk ratio in using ICT for apathy NPT, and 
13 participants out of 15 agreed that ICT can be used to continue or maintain adherence to the 
intervention without the presence of the therapist. As detailed below, the experts highlighted the 
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importance of considering the degree of patients’ cognitive and functional impairment in order to 
evaluate the usability of ICT-based NPT. The presence of a caregiver was considered as critical for 
people with advanced impairment at the cognitive and functional level.  
Telemedicine platforms. Participants reported that it is ‘very appropriate’ to deliver NPT 
remotely by employing ICTs, such as tele-medicine platforms and Virtual Reality environments 
(Q11) for individual sessions, while it is ‘adapted’ for group sessions. Video-conference, audio-
conference, Virtual Reality (VR) immersive environments and the use of a virtual coach were all 
rated as ‘very appropriate’ to deliver NPT treatments remotely (Q12), with the lowest scores 
(‘appropriate’) assigned to audio-conference platforms. Based on ongoing clinical trials, the experts 
suggested that the selected platform should allow monitoring online of a patient’s reactions to 
treatment, as well as to verify that the patient is following the treatment correctly
37
. The decision of 
which platform to employ should be taken based on which elements are important to capture. For 
instance, in physical training it is important that patient and therapist can see each other. However, a 
VR interface in which patient and therapist can share a screen may be more adapted for cognitive 
training sessions.    
Concerning the delivery of NPTs remotely (Q13), the presence of a caregiver was rated as 
‘very important’, in order to guarantee the system usability, safety and efficacy. The level of 
cognitive and functional impairment of the patient and his/her familiarity with ICT were rated 
between ‘important’ and ‘very important’ (learning to employ ICT may be part of the patients’ 
training, depending on their level of cognitive impairment). Where the patient lives (e.g., distance 
from clinical facilities) was rated as ‘important’, and home-based and/or long-term frequent 
treatments delivered remotely may be more convenient.  
SWOT analysis of ICT for NPT 
12 
A SWOT analysis (Strengths, Weaknesses, Opportunities, and Threats) of the use of ICT for 
NPTs is reported in Table 2. 
[Table 2] 
Strengths.  ICT can help in standardizing the treatment conditions (e.g. reproducibility, contents 
and automatic follow-up), and collecting non-invasive objective, measurable and longitudinal data 
on participants’ adherence to treatment and their performance. Also, ICT is useful to tailor and 
personalize the intervention. Compared to classical treatments, ICT interventions are easier to adapt 
to the personal interests (e.g., serious games to train executive functions based on a cooking plot vs 
a naval battle plot), sensory preferences (e.g., background color of ICT interface), the level of 
impairment (e.g., through algorithms that adapt the game difficulty online, in what has been defined 
closed-loop cognition
47
), and patient’s equipment (e.g. tablets, smartphones or VR headsets). 
Furthermore, ICT can provide more immersive, stimulating, and varied treatments with the 
potential to result in higher engagement and positive emotions. Finally, ICT can provide affordable 
and easy to use options, that can also be potentially used remotely.  
Weaknesses. Some ICT-interfaces are not easy to install and use, especially for older adults, 
Relatedly, older adults may have a negative perception of ICT, as well as negative feelings 
engendered through not being able to use ICT. Furthermore, social interaction may be reduced by 
using NPT remotely. The presence of a therapist (and/or a caregiver) is a pre-requisite to mediate 
adherence to treatment, especially for people with more severe cognitive and functional impairment, 
and anosognosia. Also, newly released products can have high costs. In addition, not all high-tech 
interfaces are appropriate for people with cognitive impairment, or for specific cultural 
backgrounds, and may not embed challenges that make the training engaging. However, these 
aspects can be improved by designing interfaces tailored to specific categories of patients and 
deficits
36
. Finally, similar to classical NPT, there is a risk of accidents with remote training (e.g., 
13 
risk of falls for physical activity trainings), and potentially a risk of addictive or habitual behavior, 
specifically linked to the use of video-games.  
Opportunities. ICT is becoming increasingly affordable and easier to use. In parallel, its 
adoption is dramatically increasing (ESA, 2017). These trends represent opportunities for giving 
wider accessibility to NPT for people with apathy. Through delivering ICT-based NPT remotely, 
this would allow people living rurally, far from clinical facilities and/or with mobility problems, and 
eventually people living in middle- and low-income countries with limited access to 
neuropsychiatric centers, to get easier access to care. Also, ICT may help to deliver NPT at a large 
scale, and facilitate trainings for therapists, resulting in more standardized treatments. 
Threats. ICT-based NPT (e.g., serious games, VR) often requires a long, expensive 
technical development and can be difficult to modify once it is released. Also, there is currently 
insufficient consistent evidence regarding the effectiveness, risk and impact, as well as cross-
cultural validation of both classical and ICT-based NPT. Due to these limitations, ICT-based NPTs 
often result in poor acceptance in the medical community
48
.  
Discussion 
NPTs are currently employed as frontline treatments for apathy in people with different 
brain disorders
11
 and previously reported NPTs have shown initial promising results in improving 
apathy (Table 1). However, the field urgently need more methodologically-sound studies (RCT) to 
assess the efficacy of specific NPTs, and to standardize treatment materials and conditions. Here we 
gathered recommendations from experts on how to progress the field further. Converging with 
previous studies, our results suggested several important implications for clinical practice and 
research. 
Early detection of apathy. In NCD apathy can appear at the early stages of the disease 
progression
49
. Apathy is recognized as a multidimensional construct; reduction in goal-directed 
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activities can be found in the domains of behavior, cognition, emotions and social interaction
3
. To 
implement early interventions, it is necessary to assess apathy early in the disease progression. The 
experts suggested that more collaborative research would be needed for further convergence of 
understanding of the construct of apathy. The 2018 Diagnostic Criteria for Apathy (DCA)3 may be 
particularly useful in this context, as they are a) transdiagnostic, making it possible to compare 
apathy in different populations, and b) multidimensional, providing a method to obtain a composite 
apathy profile. Furthermore, c) they form the basis for potential clinical scales and ICT-based 
instruments to detect each apathy dimensions. Employing the 2018 DCA in the clinical practice 
may contribute to increasing comparability of results across clinical centers. Crucially, the experts 
recommended that future studies employ multidimensional apathy assessment (e.g., Apathy 
Motivation Index
43
; Dimensional Apathy Scale
44,45
) to better understand the differential effects of 
different NPT. Finally, impairments in apathy dimensions should also be reported for patients not 
fulfilling the DCA. Indeed, isolated symptoms such as lack of interest and/or social interaction are 
also found in a significant proportion of individuals without clinical apathy
41
. The presence of some 
isolated symptoms – for instance lack of interest - may be due to a partial overlap between apathy 
and other clinical conditions, such as depression
4
. However, symptoms may also appear in isolation 
and independently of these conditions. Knowing which isolated symptoms preceded – for months or 
years – an apathy diagnosis would help to better understand how apathy develops and unfolds over 
time.  
Early intervention. In clinical settings, symptom-specific and non-specific NPTs for apathy 
are more commonly employed in people with well-established pathological conditions
11
. However, 
in NCD apathy can appear at the early stages of the disease progression, even in people with SCD. 
The presence of apathy has been associated with a faster cognitive and functional decline
50
, 
representing a risk factor for the conversion from MCI to AD
51
. Critically, preliminary evidence 
suggests that interventions targeting apathy in people with MCI (e.g. with repetitive transcranial 
magnetic stimulation, rTMS) may be effective in improving the global cognitive functioning
33
. 
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Thus, putting in place early treatment options for MCI or even SCD might offer new opportunities 
for altering the trajectory of Alzheimer’s Disease dementia. Apathy has also been observed as 
prevalent in early stages of other neurodegenerative conditions, such as PD
52 
and ALS/MND
53
. 
Therefore, an important area for future investigate is the development of NPTs for apathy at the 
early stages of disease processes. 
Personalized therapy. Generic approaches to activities may fail to produce positive changes 
in many patients: the more the treatment is tailored to the person, the higher the probability that the 
treatment is effective
54
. At a clinical level, “tailor-made” approaches are required, including 
designing specific meaningful activities depending on individuals’ interests, needs, abilities and 
capacities
55
, and in line with their perceived self and identity
56
. Sensory preferences (e.g. what the 
person likes to touch, smell, eat, his/her favorite colors and music) of the person are also important 
aspects to consider. Further, collecting personal interests, needs, preferences and identities are not 
trivial when dealing with people with neurocognitive and neuropsychiatric disorders. At a research 
level, it is important to develop instruments that would be able to capture these aforementioned 
preference dimensions in a standardized way. Semi-structured interviews and serious games 
represent such promising instruments.   
The role of ICT. In line with previous recommendations
48,57
, the experts suggested that ICT 
may play an important role in NPT for apathy. The use of ICT in NPT for apathy is still in an early 
phase of development, characterized by encouraging initial research results
48
. The many listed 
strengths - including improving treatment standardization, non-invasive and continuous monitoring 
of patients’ apathy, and remote treatment delivery - provide a justification for further development 
of ICT as NPT for apathy. However, some weaknesses were noted (in particular concerning the 
difficulty that older patients experience with using ICT alone), as well as some threats, none of 
which were deemed to be major. At the practical level, it would be important to develop easy-to-
use, affordable ICT solutions for clinicians that can be implemented in everyday practice, and 
16 
potentially be employed remotely, with the help of a caregiver. At a research level, it is important to 
collect methodologically-sound data to test and evolve usability, usefulness and efficacy of ICT-
based NPTs targeting people with brain disorders.  
In summary, through expert consensus, improving early detection and early treatment may 
be valuable in characterizing and managing apathy as a syndrome in brain disorders. Furthermore, 
personalized NPT approaches for apathy may provide stronger evidence of NPT efficacy, which 
would result in clearer guidelines for NPT prescription or administration and delivery. ICT may 
play a role in facilitating NPT delivery, standardization and assessment, provide a potential future 
avenue for development methods of management, treatment and interventions for apathy. 
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Table 1: Different types of NPT used in different populations with apathy as a direct or indirect target.  
 
Approach  Description of the intervention Mainly used in  
Art Therapy Form of psychotherapy that uses art 
media as its primary mode of 
communication to enable a patient to 
change and grow on a personal level 
through the use of art materials in a 
safe and facilitating environment. 
Mild and Major NCD (including 
AD, all stages)11  
Cognitive interventions  Cognitive stimulation, training or 
rehabilitation designed to solicit one or 
more cognitive functions such as 
attention, memory, language, 
orientation to maintain, improve or 
compensate for them. This includes 
both classical and computerized 
interventions (e.g., serious-games) 
Mild and Major NCD17,18; PSP19, 
Schizophrenia20; PD21; Acute 
Stroke22 
Animal assisted Therapy 
(AAT) 
Based on patient-animal-therapist 
interaction, AAT is an individual or 
group intervention carried out in care 
settings by a professional to improve 
mental, cognitive, physical, social 
and/or emotional functioning of 
patient.  
AD (moderate stage)23 
Motivational 
Interviewing 
Collaborative client-centered approach 
designed to enhance internal 
motivation for behavior change 
through the reduction of patient 
ambivalence feelings. It is based on 
several social and behavioral principals 
such as empathy, decisional balance 
and reduction of resistance to change. 
TBI24 
Physiotherapy Science-based profession aimed to help 
people affected by injury, illness or 
disability through movement and 
exercise, manual therapy, education 
Acute Stroke25, PD26 
23 
and advice. 
Multi-sensory 
Stimulation/Snoezelen 
Person-centered care approach using 
i.e lights, aroma therapy, music/sounds, 
tactile objects, and/or screen projectors 
in an immersive environment to 
actively stimulate one or more of the 
different senses (vision, audition, tact, 
olfaction and taste).   
Major NCD11 
Music therapy Clinical active or receptive 
interventions using music, its 
instruments and properties in 
individual or group settings to optimize 
people’s quality of life and improve 
their different functions (physical, 
social, communicative, emotional, 
intellectual). 
Mild and Major NCD (including 
AD, all stages)11 
Occupational therapy 
(OT) interventions 
In a client-centered care approach, OT 
accompanies people encountering 
disability situations in order to 
improve, maintain or compensate their 
participation in activities of daily 
living. With regards to Apathy, OT can 
provide to the patient and his/her 
caregiver with more engaging and 
personalized strategies and a program 
of tailored activities, customized to 
previous and current interests, residual 
functional capacities and patient’s level 
of cognitive decline. 
Mild and Major NCD (including 
AD, all stages)11,27,28; PD29  
Physical activity Physical exercise can have positive 
effects on both physical function and 
mental health.  Physical exercise can 
aim to improve muscle strengths (lower 
and upper limbs), balance, mobility, 
and to reduce stress. Examples of 
activities include: strengthening and 
balance exercises, cycling, swimming, 
yoga and Pilates.  
PD26; Major NCD and Stroke30 
Reminiscence Therapy based on the evocation and Major NCD (including AD, all 
24 
discussion about personal past 
activities, events and life experiences, 
in individual or group settings, using a 
variety of supporting meaningful 
materials. 
stages)11 
Assistive social robots Therapeutic or recreational 
interventions that use social robots 
(animal-like, human-like) as a support 
to promote communication, reduce 
loneliness and improve the emotional 
state of the user. 
Major NCD11 
Staff or caregiver 
education program 
The learning of behavioural strategies 
to manage apathy in care settings or in-
home care and reduce its negative 
consequences. 
Neurological conditions (AD, PD, 
etc.)31; Mild NCD27; PSP19 
Virtual Reality (VR) VR is an ICT used in healthcare setting 
to help diagnosis or to treat cognitive, 
psychological or physical pathologies. 
Its strengths consist of ecological 
validity, which can facilitate the 
transfer of VR learning to the real 
world, its ludic aspect and the 
possibility of personalization of the 
immersive environment. 
Mild NCD32 
Repetitive Transcranial 
Magnetic Stimulation 
(rTMS) 
Non-invasive treatment consisting of 
magnetic stimulation sessions using a 
figure-of-eight-shaped coil applied on a 
target cranial surface in ordered to 
increase cortical activity and modulate 
cerebral networks. 
Mild NCD33; PD34; Chronic stroke35 
NCD = Neurocognitive Disorder; PD = Parkinson’s Disease; TBI = Traumatic Brain Injury; AD = 
Alzheimer’s Disease; PSP = Progressive Supranuclear Palsy 
Table 2. Summary of a SWOT analysis of using ICT for apathy NPT 
Strengths Weaknesses 
- Can facilitate reproducibility and 
standardization (contents and automatic 
- Time-consuming setup (for some devices) 
- ICT interfaces and software difficult to use 
25 
follow-up) 
- Increased ecological validity, can put a 
patient in a 'reality-like' setting but more 
controlled 
- Possibility to record patient activity and 
adherence to treatment automatically, 
longitudinally and remotely, on-line or off-
line;  
- Possibility to record and analyze several 
"indirect" data (voice, movements, etc.) 
- Adaptation to the user (e.g., impairment 
type and level, personal interest) 
- Increased variety of activities, and easy 
content adaptation (themes, ergonomics) to 
increase engagement 
- Flexibility of use (multiple supports: tablet, 
smartphone, computer, tv screen...)  
- Can increase motivation, curiosity, 
immersion and positive emotions 
- Can stimulate attention and other 
cognitive processes in a controlled 
environment  
- Useful for long training sessions, allowing 
to extend patient activity at home  
- Cost-effectiveness (e.g., tablets, actigraphy) 
- Easy setup (for some devices)  
- No requirement of a therapist to be present 
all the time 
- Can be used for group stimulations 
- Poor understanding (and fear of not 
understanding) of the technology 
- Need of patients’ and staff’s training  
- Need of caregivers’ implication for people 
with Major Neurocognitive Disorder 
- Expensive equipment (e.g., VR headsets) 
- Absence of human contact (risk of 
reducing the opportunities of social 
interaction) 
- Possibility of poor engagement/interest 
- Games not embedding cognitive challenges 
- Games potentially not appropriate for 
participant's cognitive profile and culture 
- Lack of generalization to patient's 
environment (activities far from reality) 
- Side effects such as hallucinations, loss of 
sense of reality (e.g. for Virtual Reality) 
- Risk of accidents (e.g., risk of falls, 
increased sleep disturbances) 
- Risk of addiction  
- Low standardization 
Opportunities Threats 
- Emerging advances in technology 
- Good accessibility for users, also remotely 
(at home or in remote clinical facilities)  
- Increasing number of seniors commonly 
using ICT 
- Could help reducing barriers in access to 
care in middle- and low-income countries 
with limited access to neuropsychiatric 
centers 
- Usable at large scale 
- Can be used trans-diagnostically 
- Can facilitate training sessions for 
therapists  
 
- Long and expensive technical 
development, difficult to modify 
- Low experience in ICT by users 
- Cognitive/behavioral fundamentals of the 
classical therapies are not fully reproduced 
- Not enough research evidence towards 
effectiveness, risk and impact. 
- Absence of cross-cultural validation of 
NTP, and inappropriate adoption in non-
adapted cultural domains. 
- Unrealistic belief that ICT can remedy 
everything 
- Digital divide 
- Poor acceptance in the medical community 
 
 
 
